The safety and efficacy of ±3,4-methylenedioxymethamphetamineassisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder

This course page summarizes a clinical trial on the safety and efficacy of ±3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy for people with chronic, treatment-resistant posttraumatic stress disorder (PTSD). The study reviewed patients who had not responded to psychotherapy or psychopharmacology and compared MDMA-assisted psychotherapy with placebo. The trial structure included two 8-hour experimental psychotherapy sessions, with preparatory and follow-up non-drug psychotherapy for both groups. Outcomes included PTSD symptom severity, neurocognitive testing, and monitoring of blood pressure and temperature. The report is relevant for clinicians, researchers, and others interested in psychedelic-assisted therapy and PTSD treatment research. It presents findings on clinical response and safety outcomes from an early randomized controlled pilot study.